Search Results - "Ferrara, James L"

Graft-versus-host disease by Ferrara, James LM, Prof, Levine, John E, Prof, Reddy, Pavan, MD, Holler, Ernst, Prof

“…Summary Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk haematological malignant disorders and other life-threatening…”
Get full text

EBMT−NIH−CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment by Schoemans, Helene M., Lee, Stephanie J., Ferrara, James L., Wolff, Daniel, Levine, John E., Schultz, Kirk R., Shaw, Bronwen E., Flowers, Mary E., Ruutu, Tapani, Greinix, Hildegard, Holler, Ernst, Basak, Grzegorz, Duarte, Rafael F., Pavletic, Steven Z.

“…Several international recommendations address the assessment of graft-versus-host disease (GvHD) after hematopoietic cell transplantation (HCT). This position…”
Get full text

ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death by Vander Lugt, Mark T, Braun, Thomas M, Hanash, Samir, Ritz, Jerome, Ho, Vincent T, Antin, Joseph H, Zhang, Qing, Wong, Chee-Hong, Wang, Hong, Chin, Alice, Gomez, Aurélie, Harris, Andrew C, Levine, John E, Choi, Sung W, Couriel, Daniel, Reddy, Pavan, Ferrara, James L.M, Paczesny, Sophie

“…Serum levels of an interleukin-1 receptor family member called suppressor of tumorigenicity 2 (ST2) predict response to therapy for graft-versus-host disease…”
Get full text

Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease by Ferrara, James L.M., Harris, Andrew C., Greenson, Joel K., Braun, Thomas M., Holler, Ernst, Teshima, Takanori, Levine, John E., Choi, Sung W.J., Huber, Elisabeth, Landfried, Karin, Akashi, Koichi, Vander Lugt, Mark, Reddy, Pavan, Chin, Alice, Zhang, Qing, Hanash, Samir, Paczesny, Sophie

“…There are no plasma biomarkers specific for GVHD of the gastrointestinal (GI) tract, the GVHD target organ most associated with nonrelapse mortality (NRM)…”
Get full text

Advances in predicting acute GVHD by Harris, Andrew C., Ferrara, James L. M., Levine, John E.

“…Summary Acute graft‐versus‐host disease (GVHD) is a leading cause of non‐relapse mortality following allogeneic haematopoietic cell transplantation. Attempts…”
Get full text

Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study by Levine, John E., Logan, Brent R., Wu, Juan, Alousi, Amin M., Bolaños-Meade, Javier, Ferrara, James L.M., Ho, Vincent T., Weisdorf, Daniel J., Paczesny, Sophie

“…Acute graft-versus-host disease (GVHD) is the primary limitation of allogeneic hematopoietic cell transplantation, and once it develops, there are no reliable…”
Get full text

A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study by Levine, John E, Prof, Braun, Thomas M, Prof, Harris, Andrew C, MD, Holler, Ernst, MD, Taylor, Austin, BA, Miller, Holly, DO, Magenau, John, MD, Weisdorf, Daniel J, Prof, Ho, Vincent T, MD, Bolaños-Meade, Javier, MD, Alousi, Amin M, MD, Ferrara, James L M, Prof

“…Summary Background Graft-versus-host disease (GVHD) is the major cause of non-relapse mortality after allogeneic haemopoietic stem-cell transplantation (SCT)…”
Get full text

Plasma biomarkers of lower gastrointestinal and liver acute GVHD by Harris, Andrew C., Ferrara, James L.M., Braun, Thomas M., Holler, Ernst, Teshima, Takanori, Levine, John E., Choi, Sung W., Landfried, Karin, Akashi, Koichi, Lugt, Mark Vander, Couriel, Daniel R., Reddy, Pavan, Paczesny, Sophie

“…The lower gastrointestinal tract (LGI) and liver are the GVHD target organs most associated with treatment failure and nonrelapse mortality. We recently…”
Get full text

Elafin is a biomarker of graft-versus-host disease of the skin by Paczesny, Sophie, Braun, Thomas M, Levine, John E, Hogan, Jason, Crawford, Jeffrey, Coffing, Bryan, Olsen, Stephen, Choi, Sung W, Wang, Hong, Faca, Vitor, Pitteri, Sharon, Zhang, Qing, Chin, Alice, Kitko, Carrie, Mineishi, Shin, Yanik, Gregory, Peres, Edward, Hanauer, David, Wang, Ying, Reddy, Pavan, Hanash, Samir, Ferrara, James L M

“…Graft-versus-host disease (GVHD), the major complication of allogeneic bone marrow transplantation, affects the skin, liver, and gastrointestinal tract. There…”
Get more information

Microbial metabolite sensor GPR43 controls severity of experimental GVHD by Fujiwara, Hideaki, Docampo, Melissa D., Riwes, Mary, Peltier, Daniel, Toubai, Tomomi, Henig, Israel, Wu, S. Julia, Kim, Stephanie, Taylor, Austin, Brabbs, Stuart, Liu, Chen, Zajac, Cynthia, Oravecz-Wilson, Katherine, Sun, Yaping, Núñez, Gabriel, Levine, John E., van den Brink, Marcel R.M., Ferrara, James L. M., Reddy, Pavan

“…Microbiome-derived metabolites influence intestinal homeostasis and regulate graft-versus-host disease (GVHD), but the molecular mechanisms remain unknown…”
Get full text

Programmed death-1 controls T cell survival by regulating oxidative metabolism by Tkachev, Victor, Goodell, Stefanie, Opipari, Anthony W, Hao, Ling-Yang, Franchi, Luigi, Glick, Gary D, Ferrara, James L M, Byersdorfer, Craig A

“…The coinhibitory receptor programmed death-1 (PD-1) maintains immune homeostasis by negatively regulating T cell function and survival. Blockade of PD-1…”
Get full text

Adverse functions of IL-17A in experimental sepsis by Flierl, Michael A, Rittirsch, Daniel, Gao, Hongwei, Hoesel, Laszlo M, Nadeau, Brian A, Day, Danielle E, Zetoune, Firas S, Sarma, J. Vidya, Huber-Lang, Markus S, Ferrara, James L.M, Ward, Peter A

“…IL-17A is a proinflammatory cytokine produced by a variety of cells. In the current study, we examined the role of IL-17A in sepsis induced in mice by cecal…”
Get full text

Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers by Kasikis, Stelios, Baez, Janna, Gandhi, Isha, Grupp, Stephan, Kitko, Carrie L., Kowalyk, Steven, Merli, Pietro, Morales, George, Pulsipher, Michael A., Qayed, Muna, Wölfl, Matthias, Yanik, Gregory, See, Fiona, Hayes, Jack, Grossman, Fred, Burke, Elizabeth, Young, Rachel, Levine, John E., Ferrara, James L. M.

Get full text

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial by Pidala, Joseph, Hamadani, Mehdi, Dawson, Peter, Martens, Michael, Alousi, Amin M., Jagasia, Madan, Efebera, Yvonne A., Chhabra, Saurabh, Pusic, Iskra, Holtan, Shernan G., Ferrara, James L.M., Levine, John E., Mielcarek, Marco, Anasetti, Claudio, Antin, Joseph H., Bolaños-Meade, Javier, Howard, Alan, Logan, Brent R., Leifer, Eric S., Pritchard, Theresa S., Horowitz, Mary M., MacMillan, Margaret L.

“…Clinical- and biomarker-based tools may identify a lower-risk acute graft-versus-host disease (GVHD) population amenable to novel, reduced-intensity…”
Get full text

Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant by Aziz, Mina D., Shah, Jay, Kapoor, Urvi, Dimopoulos, Christina, Anand, Sarah, Augustine, Allan, Ayuk, Francis, Chaudhry, Mohammed, Chen, Yi-Bin, Choe, Hannah K., Etra, Aaron, Gergoudis, Stephanie, Hartwell, Matthew J., Hexner, Elizabeth O., Hogan, William J., Kitko, Carrie L., Kowalyk, Steven, Kröger, Nicolaus, Merli, Pietro, Morales, George, Nakamura, Ryotaro, Ordemann, Rainer, Pulsipher, Michael A., Qayed, Muna, Reshef, Ran, Rösler, Wolf, Schechter, Tal, Schreiner, Elisabeth, Srinagesh, Hrishikesh, Wölfl, Matthias, Wudhikarn, Kitsada, Yanik, Gregory, Young, Rachel, Özbek, Umut, Ferrara, James L. M., Levine, John E.

“…The graft-versus-leukemia (GVL) effect after allogeneic hematopoietic cell transplant (HCT) can prevent relapse but the risk of severe graft-versus-host…”
Get full text

Tisch Cancer Institute Scholars Program: Mentored Cancer Research Training Pipeline for Medical Students by Ben-David, Kaitlyn, Lin, Jenny J., Ferrara, James L. M., Gabrilove, Janice L.

“…Cancer research has led to unprecedented advances in treatment in recent decades. Physician-scientists have played a crucial role in these advances given their…”
Get full text

Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease by Levine, John E., Paczesny, Sophie, Mineishi, Shin, Braun, Thomas, Choi, Sung W., Hutchinson, Raymond J., Jones, Dawn, Khaled, Yasser, Kitko, Carrie L., Bickley, Daniel, Krijanovski, Oleg, Reddy, Pavan, Yanik, Gregory, Ferrara, James L.M.

“…Graft-versus-host disease (GVHD) is a principal cause of morbidity following allogeneic hematopoietic cell transplantation (HCT). Standard therapy for GVHD,…”
Get full text

Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality by Levine, John E., Huber, Elisabeth, Hammer, Suntrea T.G., Harris, Andrew C., Greenson, Joel K., Braun, Thomas M., Ferrara, James L.M., Holler, Ernst

“…Acute graft-versus-host disease (GVHD) of the gastrointestinal (GI) tract is an often lethal complication of allogeneic hematopoietic cell transplant. Clinical…”
Get full text

Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival by Choi, Sung W., Kitko, Carrie L., Braun, Thomas, Paczesny, Sophie, Yanik, Gregory, Mineishi, Shin, Krijanovski, Oleg, Jones, Dawn, Whitfield, Joel, Cooke, Kenneth, Hutchinson, Raymond J., Ferrara, James L.M., Levine, John E.

“…Acute graft-versus-host disease (GVHD) remains a significant cause of mortality after hematopoietic cell transplantation (HCT). Tumor necrosis factor–alpha…”
Get full text

Acute graft-versus-host disease: new treatment strategies by Paczesny, Sophie, Choi, Sung W, Ferrara, James LM

“…PURPOSE OF REVIEWGraft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT),…”
Get full text